Dynamic remodeling of the KRAS interactome by direct RAS inhibitors with distinct mechanism of action reveals convergent responses
- 1Novartis Biomedical Research, San Diego, CA USA
Abstract
KRAS is mutated in 30% of all human cancers. Small molecule inhibitors targeting KRAS with distinct mechanisms-of-action and variable specificities have entered the clinic, but their full effect on the RAS signaling network remains unclear. Here, we described the impact of RAS inhibition on the KRAS interactome using Proximity-dependent Biotin Identification. Two inhibitors were used: panRAS-ON, which forms a ternary complex between cyclophilin and RAS in the GTP-bound state; panKRAS-off, which binds to the KRAS switch II pocket. RAS inhibitors were found to significantly alter 16.5% of proteins in proximity to KRAS. Despite their distinct modality, the KRAS inhibitors induced highly correlated changes in the KRAS interactomes. Among KRAS-proximal proteins, Afadin was highly affected by RAS inhibition. AFDN is a key regulator of cell motility, invasion, and metastasis. Analysis of AFDN phosphorylation revealed that AKT only partially modulates p-Ser1718, while KRAS inhibition sufficiently abolished EGF-mediated AFDN phosphorylation. Silencing AFDN in a KRAS-driven non-small cell lung cancer model abolished chemotaxis and disrupted directional migration in an EGF-driven wound healing model. We demonstrated that KRAS is a central node in regulating growth factor-induced cell migration, and that KRAS inhibition plays a broader role than MAPK-mediated cell proliferation and survival.
Related
- Multi-Omic Integration of the miRNome and Transcriptome in Dermal Fibroblasts from Hypermobile Ehlers–Danlos Syndrome and Hypermobility Spectrum Disorders Identifies Convergent Candidate miRNA-mRNA Regulatory Networks Linking Extracellular Matrix Remodeling and Inflammation
- Cryo-EM structures reveal the mechanism of phosphatidylserine remodeling by membrane-bound glycerophospholipid O-acyltransferase 1
- Mapping the Nonhistone Interactome of the TRIM24 Bromodomain Using Genetically Encoded Complementary Photocrosslinkers
- Bioinformatic prediction, qCLASH, and AlphaFold3 reveal non-overlapping layers of the miR-214-3p–mRNA interactome
- A sensitive Interactome-based approach to characterize drug activity in living human cells
BibTeX
@article{yang2026dynamic,
title = {{Dynamic remodeling of the KRAS interactome by direct RAS inhibitors with distinct mechanism of action reveals convergent responses}},
author = {Yang Yang and Tingyu Liu and Charles Y. Cho and Xianzhong Liu and Ansgar Brock and Doug Quackenbush and Kaisheng Chen and Frederick Lo and Cyril H. Benes and Jacob R. Haling},
journal = {Oncogene},
year = {2026},
month = oct,
doi = {10.1038/s41388-026-04017-y},
url = {https://doi.org/10.1038/s41388-026-04017-y},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Dynamic remodeling of the KRAS interactome by direct RAS inhibitors with distinct mechanism of action reveals convergent responses
AU - Yang Yang
AU - Tingyu Liu
AU - Charles Y. Cho
AU - Xianzhong Liu
AU - Ansgar Brock
AU - Doug Quackenbush
AU - Kaisheng Chen
AU - Frederick Lo
AU - Cyril H. Benes
AU - Jacob R. Haling
PY - 2026
DA - 2026/10/16
JO - Oncogene
DO - 10.1038/s41388-026-04017-y
UR - https://doi.org/10.1038/s41388-026-04017-y
AB - KRAS is mutated in 30% of all human cancers. Small molecule inhibitors targeting KRAS with distinct mechanisms-of-action and variable specificities have entered the clinic, but their full effect on the RAS signaling network remains unclear. Here, we described the impact of RAS inhibition on the KRAS interactome using Proximity-dependent Biotin Identification. Two inhibitors were used: panRAS-ON, which forms a ternary complex between cyclophilin and RAS in the GTP-bound state; panKRAS-off, which binds to the KRAS switch II pocket. RAS inhibitors were found to significantly alter 16.5% of proteins in proximity to KRAS. Despite their distinct modality, the KRAS inhibitors induced highly correlated changes in the KRAS interactomes. Among KRAS-proximal proteins, Afadin was highly affected by RAS inhibition. AFDN is a key regulator of cell motility, invasion, and metastasis. Analysis of AFDN phosphorylation revealed that AKT only partially modulates p-Ser1718, while KRAS inhibition sufficiently abolished EGF-mediated AFDN phosphorylation. Silencing AFDN in a KRAS-driven non-small cell lung cancer model abolished chemotaxis and disrupted directional migration in an EGF-driven wound healing model. We demonstrated that KRAS is a central node in regulating growth factor-induced cell migration, and that KRAS inhibition plays a broader role than MAPK-mediated cell proliferation and survival.
SN - 0950-9232
SN - 1476-5594
ER -